Nigeria Looks to Simple Packaging Controls and International Cooperation to Curb Counterfeit Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nigeria Looks to Simple Packaging Controls and International Cooperation to Curb Counterfeit Drugs


ePT--the Electronic Newsletter of Pharmaceutical Technology

The distribution of counterfeit drugs is a serious problem in Nigeria, as in many developing nations, driven by the desire of an impoverished population for drugs at the lowest possible price. A recent video report from CNN highlights Nigeria’s response to this problem, which includes vigilant police work, and a novel strategy for easily identifying legitimate products adopted by some Nigerian manufacturers:  

The strategy is the innovation of the Boston-based company Sproxil, and relies on a code contained on a scratch card within the drug packaging. Consumers can enter the code by phone and receive instant confirmation that the product is legitimate.  Manufacturers pay for the service and have been able to recapture market share from the counterfeit market. In CNN’s video, Dr. Ashifi Gogo, CEO of Sproxil states: “In a sense, the counterfeiters are paying for this service, which puts a smile on everyone’s face, except the counterfeiters.”

In addition to local solutions, Nigeria is reaching out to its trade partners to help combat this problem. On Mar. 16, 2011, a Memorandum of Understanding in the field of pharmaceuticals was signed between Nigeria’s Department of Pharmaceuticals and India’s National Agency for Food and Drug Administration and Control. Among other things, the document outlines policies that will help promote mutual trade in good quality drugs, drug testing and analysis, and detection and prevention of the supply of adulterated, fake, drugs. The agreement stipulates a stiff penalty ¾ life imprisonment ¾ for Indians caught producing or distributing counterfeit pharmaceuticals in Nigeria, as well as confiscation of property by the government.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here